FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3152309306> ?p ?o ?g. }

• W3152309306 endingPage "9496" @default.
• W3152309306 startingPage "9486" @default.
• W3152309306 abstract "AIM:To determine the relationship between host immunity and the characteristics of viral infection or nucleoside analogues(NAs)themselves in patients with chronic hepatitis B(CHB)receiving NA therapy.METHODS:Fifty-two hepatitis B envelope antigen(HBeAg)positive CHB patients were enrolled and divided equally into two groups.One group received telbivudine(LDT,600 mg/d),and the other group received lamivudine(LAM,100 mg/d).Clinical,virological and immunological parameters were assessed at the baseline and at 4,12,24,36 and 48 wk.RESULTS:Both groups achieved significant hepatitis B virus(HBV)replication inhibition and alanine aminotransferase normalization at 48 wk.At the baseline,compared to healthy controls,CHB patients had a lower circulating CD8 T cell frequency(29.44%±11.55%vs 37.17%±7.30%,p=0.03)and higher frequencies of programmed death 1 positive CD8 T cells(pD-1+CD8 T)(16.48%±10.82%vs 7.02%±3.62%,p=0.0001)and CD4+CD25+Foxp3+T regulatory cells(Tregs)(23.64%±9.38%vs 13.60%±6.06%,p=0.001).On therapy,at the beginning 24 wk with the levels of hepatitis B virus deoxyribonucleic acid(HBV DNA)and HBeAg declining,the frequencies of pD-1+CD8 T cells and Treg cells gradually and significantly declined at 12 and 24 wk in both therapy groups.At treatment week 4,patients treated with LDT had a lower frequency of pD-1+CD8 T cells compared to patients treated with LAM(10.08%±6.83%vs 20.51%±20.96%,p=0.02).The frequency of pD-1+CD8 T cells in all of the CHB patients was significantly correlated with both the HBV DNA level(r=0.45,p=0.01)and HBeAg level(r=0.47,p=0.01)at treatment week 24,but the frequency of Treg cells was only significantly correlated with the HBeAg level(r=0.44,p=0.02).Furthermore,the ability of CD8 T cells to secrete pro-inflammatory cytokines was partially restored after 24 wk of therapy.CONCLUSION:NA-mediated HBV suppression could down-regulate the production of negative regulators of host immunity during the first 24 wk of therapy and could partially restore the ability of CD8 T cells to secrete p" @default.
• W3152309306 created "2021-04-13" @default.
• W3152309306 creator A5005037408 @default.
• W3152309306 creator A5006579524 @default.
• W3152309306 creator A5025879011 @default.
• W3152309306 creator A5031574504 @default.
• W3152309306 creator A5035695396 @default.
• W3152309306 creator A5043499959 @default.
• W3152309306 creator A5043592576 @default.
• W3152309306 creator A5052500563 @default.
• W3152309306 creator A5053780153 @default.
• W3152309306 creator A5060073997 @default.
• W3152309306 creator A5074390488 @default.
• W3152309306 creator A5077465517 @default.
• W3152309306 creator A5081377873 @default.
• W3152309306 creator A5085393851 @default.
• W3152309306 creator A5087708539 @default.
• W3152309306 creator A5090151860 @default.
• W3152309306 date "2014-01-01" @default.
• W3152309306 modified "2023-09-23" @default.
• W3152309306 title "Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B" @default.
• W3152309306 hasPublicationYear "2014" @default.
• W3152309306 type Work @default.
• W3152309306 sameAs 3152309306 @default.
• W3152309306 citedByCount "0" @default.
• W3152309306 crossrefType "journal-article" @default.
• W3152309306 hasAuthorship W3152309306A5005037408 @default.
• W3152309306 hasAuthorship W3152309306A5006579524 @default.
• W3152309306 hasAuthorship W3152309306A5025879011 @default.
• W3152309306 hasAuthorship W3152309306A5031574504 @default.
• W3152309306 hasAuthorship W3152309306A5035695396 @default.
• W3152309306 hasAuthorship W3152309306A5043499959 @default.
• W3152309306 hasAuthorship W3152309306A5043592576 @default.
• W3152309306 hasAuthorship W3152309306A5052500563 @default.
• W3152309306 hasAuthorship W3152309306A5053780153 @default.
• W3152309306 hasAuthorship W3152309306A5060073997 @default.
• W3152309306 hasAuthorship W3152309306A5074390488 @default.
• W3152309306 hasAuthorship W3152309306A5077465517 @default.
• W3152309306 hasAuthorship W3152309306A5081377873 @default.
• W3152309306 hasAuthorship W3152309306A5085393851 @default.
• W3152309306 hasAuthorship W3152309306A5087708539 @default.
• W3152309306 hasAuthorship W3152309306A5090151860 @default.
• W3152309306 hasConcept C126322002 @default.
• W3152309306 hasConcept C159047783 @default.
• W3152309306 hasConcept C167672396 @default.
• W3152309306 hasConcept C203014093 @default.
• W3152309306 hasConcept C2522874641 @default.
• W3152309306 hasConcept C2775940106 @default.
• W3152309306 hasConcept C2776090121 @default.
• W3152309306 hasConcept C2776543447 @default.
• W3152309306 hasConcept C2777333352 @default.
• W3152309306 hasConcept C2777382497 @default.
• W3152309306 hasConcept C2777410769 @default.
• W3152309306 hasConcept C2777869810 @default.
• W3152309306 hasConcept C2780593183 @default.
• W3152309306 hasConcept C2781144229 @default.
• W3152309306 hasConcept C3017875465 @default.
• W3152309306 hasConcept C55493867 @default.
• W3152309306 hasConcept C71924100 @default.
• W3152309306 hasConcept C79484868 @default.
• W3152309306 hasConcept C86803240 @default.
• W3152309306 hasConcept C8891405 @default.
• W3152309306 hasConcept C90924648 @default.
• W3152309306 hasConceptScore W3152309306C126322002 @default.
• W3152309306 hasConceptScore W3152309306C159047783 @default.
• W3152309306 hasConceptScore W3152309306C167672396 @default.
• W3152309306 hasConceptScore W3152309306C203014093 @default.
• W3152309306 hasConceptScore W3152309306C2522874641 @default.
• W3152309306 hasConceptScore W3152309306C2775940106 @default.
• W3152309306 hasConceptScore W3152309306C2776090121 @default.
• W3152309306 hasConceptScore W3152309306C2776543447 @default.
• W3152309306 hasConceptScore W3152309306C2777333352 @default.
• W3152309306 hasConceptScore W3152309306C2777382497 @default.
• W3152309306 hasConceptScore W3152309306C2777410769 @default.
• W3152309306 hasConceptScore W3152309306C2777869810 @default.
• W3152309306 hasConceptScore W3152309306C2780593183 @default.
• W3152309306 hasConceptScore W3152309306C2781144229 @default.
• W3152309306 hasConceptScore W3152309306C3017875465 @default.
• W3152309306 hasConceptScore W3152309306C55493867 @default.
• W3152309306 hasConceptScore W3152309306C71924100 @default.
• W3152309306 hasConceptScore W3152309306C79484868 @default.
• W3152309306 hasConceptScore W3152309306C86803240 @default.
• W3152309306 hasConceptScore W3152309306C8891405 @default.
• W3152309306 hasConceptScore W3152309306C90924648 @default.
• W3152309306 hasIssue "28" @default.
• W3152309306 hasLocation W31523093061 @default.
• W3152309306 hasOpenAccess W3152309306 @default.
• W3152309306 hasPrimaryLocation W31523093061 @default.
• W3152309306 hasRelatedWork W2006178549 @default.
• W3152309306 hasRelatedWork W2060737206 @default.
• W3152309306 hasRelatedWork W2089304757 @default.
• W3152309306 hasRelatedWork W2104511484 @default.
• W3152309306 hasRelatedWork W2337053813 @default.
• W3152309306 hasRelatedWork W2353387844 @default.
• W3152309306 hasRelatedWork W2360223401 @default.
• W3152309306 hasRelatedWork W2363183902 @default.
• W3152309306 hasRelatedWork W2369002051 @default.
• W3152309306 hasRelatedWork W2369295398 @default.

• next